|
Session 106
Poster Abstracts
Impact of Resistance on Treatment Response
Tuesday, 1:30 - 3:30 pm
Poster Hall |
| 632 |
Baseline Genotype/Phenotype, Virological Response, and Lack of de novo Resistance Mutation Generation during Therapy with Dexelvucitabine (Formerly Reverset) in Study RVT-203
Susan Erickson-Viitanen*1, K Hou1, R Lloyd Jr2, R Mathis2, D Burns2, R Goyvaerts3, and R Levy1
1Incyte, Wilmington, DE, US; 2Research Think Tank, Alpharetta, GA, US; and 3Virco, Mechelen, Belgium |
| 633 |
K65R, L74V and Thymidine Analog Mutations in HIV-1 RT Associated with Reduced Response to Tenofovir DF in ART-experienced Patients
J Waters1, N Margot2, D McColl2, L Zhong2, and Michael Miller*2
1Gilead Sci, Durham, NC, US and 2Gilead Sci, Foster City, CA, US |
| 634 |
Evaluation of Phenotypic Clinical Cutoff for Atazanavir/Ritonavir in Patients Who Changed Only the Protease Inhibitor Component of HAART: A Confirmatory Week 2 Analysis of AI424-045
Eoin Coakley*1, C Chappey1, J Maa2, S Wang2, M Bates1, R Pesano1, A Thirty2, and D Seekins2
1Monogram Biosci, South San Francisco, CA, US and 2Bristol-Myers Squibb, Plainsboro, NJ, US |
| 635 |
Intensification of a Failing Regimen with Zidovudine May Cause Sustained Virologic Suppression in the Presence of the K65R Mutation
Schlomo Staszewski*1, B Dauer1, L Locher2, M Moesch1, P Gute2, and M Stuermer1
1JW Goethe Univ, Frankfurt, Germany and 2Gemeinschaftspraxis Grueneburgweg, Frankfurt, Germany |
636
 |
Virological Response to ART in the Presence of K65R Mutation
Andrea Antinori*1, M Trotta1, P Lorenzini1, G Carosi2, N Gianotti3, F Maggiolo4, C Torti2, A Castagna3, M Andreoni5, and C F Perno1
1Natl Inst for Infectious Diseases L Spallanzani IRCCS, Rome, Italy; 2Inst of Infectious and Tropical Diseases, Univ of Brescia, Italy; 3San Raffaele Sci Inst, Vita e Salute Univ, Milan, Italy; 4Hosp Riuniti, Bergamo, Italy; and 5Univ Tor Vergata, Rome, Italy |
| 637 |
Protease Mutations Associated with Higher or Lower than Expected Tipranavir Susceptibility Based on the TPV Mutation Score
Neil T Parkin* and C Chappey
Monogram Biosci, South San Francisco, CA, US |
638
|
Clinically Relevant Interpretation of Genotype and Pharmacokinetics Parameters for Resistance to Fosamprenavir/ritonavir-based Regimens in ART-experienced Patients: Zephir Study
I Pellegrin1, G Coureau2, M Dupon1, P Morlat1, E Lazaro1, H Fleury1, S Boucher1, R Thiébaut2, J L Pellegrin1, Dominique Breilh*1, and ANRS CO3 Aquitaine Cohort
1Univ Hosp, Bordeaux, France and 2INSERM U593, Victor Segalen Univ, Bordeaux, France |
639a
|
Virologic Response to Tipranavir Based on Plasma Concentration and Baseline Resistance Parameters
Lisa Naeger*, J Zheng, and K Struble
Ctr for Drug Evaluation and Res, Food and Drug Admin, Silver Spring, MD, US |
| 639b |
Pharmacokinetic/Pharmacodynamic Analyses of TMC114 in the POWER 1 and POWER 2 Trials in Treatment-experienced HIV-infected Patients
Vanitha Sekar*, S De Meyer, T Vangeneugden, E Lefebvre, M De Pauw, B Van Baelen, E De Paepe, M P De Béthune, R Hoetelmans, and W Parys
Tibotec, Yardley, PA, US |
| 640 |
The Predictive Value of Pharmacokinetic-adjusted Phenotypic Susceptibility on Antiretroviral Response to Ritonavir-enhanced Protease Inhibitors in Subjects Who Failed Previous PI-based Regimens: ACTG A5126
Joseph J Eron*1, J G Park2, R Haubrich3, J Gerber4, S Yu2, H Wu5, and D Richman3,6
1Univ of North Carolina at Chapel Hill, US; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of California, San Diego, US; 4Univ of Colorado Hlth Sci Ctr, Denver, US; 5Univ of Rochester Sch of Med and Dentistry, NY, US; and 6VA San Diego Hlthcare System, CA, US |
| 641 |
Virologic Response to NNRTI Treatment among Women Who Took Single-dose Nevirapine 18 to 36 Months Earlier
A Coovadia1, B Marais1, E Abrams2, G Sherman3, G Barry1, S Hammer2, A Karstaedt4, J Walter2, T Meyers4, and Louise Kuhn*2
1Coronation Hosp, Johannesburg, South Africa; 2Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; 3Univ of the Witwatersrand Med Sch, Johannesburg, South Africa; and 4Chris Hani Baragwanath Hosp, Johannesburg, South Africa |
|
